GLP-1 receptor agonists × glycemic control

TrialCardiovascular diabetology2019

Effect of liraglutide on cardiac function in patients with type 2 diabetes mellitus: randomized placebo-controlled trial.

Maurice B Bizino et al.PubMed ↗Full text ↗Publisher ↗

What the trial testedas reported · 23 people · 2019

No range given

Reported higher cardiac & vascular function, no range given

+1.00pg/mL

As reported

difference 1 pg/mL, no interval

No range given

Reported higher glycemic control, no range given

+2.30mmol/mol

As reported

difference 2.3 mmol/mol, no interval

Two numbers in the abstract

the abstract, start to end

- 10 pg/mL with 95% CI between - 20 and 1 pg/mL, p = 0.07.

- 2.9 with 95% CI from - 8.1 to 2.3 mmol/mol, p = 0.27).

← favours treatmentfavours comparator →
could be chance
No interval given · direction only, strength unknown
Cardiac & vascular function
1
Glycemic control
2.3
GLP-1 receptor agonistsGlycemic controlCardiac & vascular function

GLP-1 receptor agonists × glycemic controlhelps?replicated

unlikelylikely
0.910.91 without it

GLP-1 receptor agonists × cardiac & vascular functionhelps?mixed

unlikelylikely
0.500.50 without it
← favours treatmentfavours comparator →
this papermore certainless certain
1 / 5

78 papers cite itlatest 60 shown

2019
2020
2021
2022
2023
2024
2025
2026
this paperpooled ittrialcites it

The trial

Full record →Abstract, authors, funding and every citing paper · PMID 31039778